U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT06833411) titled 'Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone' on Feb. 12.
Brief Summary: The GISCO study plans to determine whether 8-week therapy is just as effective as 26-week cortisone therapy for treating giant cell arteritis
* with tocilizumab,
* while using less cortisone.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Giant Cell Arteritis (GCA)
Intervention:
DRUG: Prednisone
Participant randomization to receive shortened (8 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
DRUG: Prednisone
Participant randomization to receive stand...